TWI818168B - 治療眼疾的方法 - Google Patents

治療眼疾的方法 Download PDF

Info

Publication number
TWI818168B
TWI818168B TW109111356A TW109111356A TWI818168B TW I818168 B TWI818168 B TW I818168B TW 109111356 A TW109111356 A TW 109111356A TW 109111356 A TW109111356 A TW 109111356A TW I818168 B TWI818168 B TW I818168B
Authority
TW
Taiwan
Prior art keywords
eye
diabetic retinopathy
beauvericin
administration
day
Prior art date
Application number
TW109111356A
Other languages
English (en)
Chinese (zh)
Other versions
TW202102252A (zh
Inventor
李水盛
蘇銘嘉
林隆誌
徐兆民
Original Assignee
資元堂生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 資元堂生物科技股份有限公司 filed Critical 資元堂生物科技股份有限公司
Publication of TW202102252A publication Critical patent/TW202102252A/zh
Application granted granted Critical
Publication of TWI818168B publication Critical patent/TWI818168B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109111356A 2019-04-03 2020-04-01 治療眼疾的方法 TWI818168B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962828616P 2019-04-03 2019-04-03
US62/828,616 2019-04-03
US201962899279P 2019-09-12 2019-09-12
US62/899,279 2019-09-12

Publications (2)

Publication Number Publication Date
TW202102252A TW202102252A (zh) 2021-01-16
TWI818168B true TWI818168B (zh) 2023-10-11

Family

ID=72662774

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109111356A TWI818168B (zh) 2019-04-03 2020-04-01 治療眼疾的方法

Country Status (7)

Country Link
US (1) US11033603B2 (enExample)
EP (1) EP3946414B1 (enExample)
JP (1) JP7461663B2 (enExample)
CN (1) CN113795268B (enExample)
SG (1) SG11202110659SA (enExample)
TW (1) TWI818168B (enExample)
WO (1) WO2020200241A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI788083B (zh) * 2021-11-03 2022-12-21 葡萄王生技股份有限公司 蟬花菌絲體活性物質用於治療黃斑部病變之用途
US20240316144A1 (en) * 2023-03-20 2024-09-26 ZIH YUAN TANG Biotechnology Co, Ltd. Pharmaceutical composition and method for inhibiting angiogenesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140371158A1 (en) * 2013-06-14 2014-12-18 Georgia Regents University Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0327316A (ja) * 1989-06-23 1991-02-05 Kitasato Inst:The 高脂血症治療剤
BRPI0615974A2 (pt) * 2005-07-27 2011-05-31 University Of Florida Research Foundation, Inc., uso de choque térmico para tratar uma doença ocular em um indivìduo, método para recrutar uma célula-tronco para um tecido ocular de um indivìduo com necessidade da mesma, uso de choque térmico para tratar uma doença ou um distúrbio ocular em um indivìduo com necessidade do mesmo, uso de choque térmico para regenerar a retina em um indivìduo com necessidade do mesmo, uso de choque térmico para reparar os danos ao epitélio pgmentar da retina em um indivìduo com necessidade do mesmo, uso de choque térmico para tratar a degeneração macular em um indivìduo com necessidade do mesmo, composição farmacêutica para o recrutamento de células-tronco, composição farmacêutica para recrutamento de células-tronco em um tecido ocular, kit e método para identificar um agente que aumenta o recrutamento de células-tronco em um tecido ocular
CN101669939A (zh) * 2009-09-22 2010-03-17 中山大学 恩镰孢菌素类化合物在制备抗耐药结核菌药物中的应用
US20140275091A1 (en) * 2013-03-15 2014-09-18 Coyote Pharmaceuticals, Inc. Ocular formulations comprising geranylgeranylacetone derivatives for intraocular delivery
CN109200066A (zh) * 2017-07-07 2019-01-15 葡萄王生技股份有限公司 蝉花活性物质及其用于预防、延缓或治疗白内障的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140371158A1 (en) * 2013-06-14 2014-12-18 Georgia Regents University Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 José Norberto Vásquez-Bonilla et al., "Biological activity of mycotoxin beauvericin in cancer cells", Rev Mex Cienc Farm, 48(4), 2017, 17-27. *

Also Published As

Publication number Publication date
US11033603B2 (en) 2021-06-15
EP3946414A1 (en) 2022-02-09
CA3132137A1 (en) 2020-10-08
JP7461663B2 (ja) 2024-04-04
WO2020200241A1 (en) 2020-10-08
EP3946414B1 (en) 2025-12-03
CN113795268A (zh) 2021-12-14
KR20210149087A (ko) 2021-12-08
JP2022528566A (ja) 2022-06-14
TW202102252A (zh) 2021-01-16
CN113795268B (zh) 2025-04-08
US20200316165A1 (en) 2020-10-08
EP3946414A4 (en) 2022-12-07
EP3946414C0 (en) 2025-12-03
SG11202110659SA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
Massin et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial
Audren et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg
US6218428B1 (en) Ophthalmic composition
US11951115B2 (en) Methods of treating retinal vasculopathies
US8097640B2 (en) Prophylactic or therapeutic agent for diabetic maculopathy
El-Nimri et al. Comparison of the effects of latanoprostene bunod and timolol on retinal blood vessel density: a randomized clinical trial
TW200410699A (en) Use of ANECORTAVE acetate for the protection of visual acuity in patients with age related macular degeneration
JP7461663B2 (ja) 眼疾患の処置方法
CN108159051B (zh) 3-甲基腺嘌呤在制备治疗视网膜下纤维化的药物中的应用
Kaneko et al. Increased retinal thinning after combination of internal limiting membrane peeling and silicone oil endotamponade in proliferative diabetic retinopathy
CA3132137C (en) Method for treating ocular diseases
JP4578593B2 (ja) 糖尿病性網膜症治療のためのスロデキサイドを含有する医薬
Schilling et al. An elusive case of cystoid macular edema
EP3331517B1 (fr) Utilisation d'hydroxycarbamide pour prevenir la non-perfusion retinienne
Lin et al. Low-dose Intravitreal Triamcinolone Combined with Vitrectomy for Proliferative Diabetic Retinopathy
Kawamura et al. Long-term stability of uveitis with faint anterior chamber flare treated with once-daily topical ophthalmic betamethasone
CN121971475A (zh) miR-125b-5p抑制剂或拮抗剂治疗和/或预防近视的用途及制剂
Mohsen Abou Shousha et al. Comparative Study of Intravitreal Ranibizumab with and Without Nepafenac Eye Drops for Center Involving Diabetic Macular Edema